Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amid Pharma ‘Landmarks’ Cipla Develops Tenofovir Prodrug

Executive Summary

Cipla’s chair Dr Yusuf Hamied highlighted a series of ‘landmarks’ along the company’s journey at its recent annual general meeting and also indicated that the firm’s tenofovir prodrug, currently in early stage development, could potentially challenge TAF.

You may also be interested in...



Cipla Chief Calls For Invigorating Focus On Repurposed Drugs

Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.

Home Gains Buoy Cipla In Q1 But US Momentum Pivotal

A strong run on home turf lifted Cipla in Q1, but US momentum with differentiated launches is what investors are keeping a sharp eye on. A China play in the respiratory space is also on the cards for the Indian firm.

Gilead's Biktarvy Profile Rises As CHMP Backs Daily HIV Therapy

Biktarvy's strength in battle against ViiV Healthcare's dolutegravir franchises is seen as a 'double-edged sword' for Gilead in HIV contest amid foreseen old drug 'cannibalization'.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC123777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel